IMMUNEONCO-B (01541) surged over 10% today. As of press time, the stock was up 13.82% to HK$14, with trading turnover reaching HK$82.22 million.

On the news front, IMMUNEONCO released its interim results for the six months ended June 30, 2025, reporting revenue of RMB 38.027 million, representing a year-on-year increase of 49,285.71%. R&D expenses reached RMB 168 million, up 41.05% compared to the same period last year. The company attributed the revenue increase primarily to recent payments received under the licensing and cooperation agreement with Axion Bio, Inc.

Pacific Securities issued a research report noting that the company's Phase II clinical trial of IMM2510 combined with chemotherapy as first-line treatment for NSCLC patients in China has achieved preliminary safety and efficacy data. The company is currently planning to initiate Phase III clinical trials. Additionally, a Phase I clinical trial of IMM2510 monotherapy for recurrent/refractory solid tumors is scheduled to launch in the United States in the second half of 2025.

The firm projects the company's operating revenue for 2025-2027 to be RMB 151 million, RMB 139 million, and RMB 675 million, respectively. The valuation of the core pipeline is expected to further improve, and the "Buy" rating is maintained.